Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of JR-051 for Patients with Fabry Disease
jRCT2080223280Phase 3Completed
- Sponsor
- JCR Pharmaceuticals
- Start
- Aug 2016
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of agalsidase beta in Fabry disease (FD), sponsored by JCR Pharmaceuticals. Started Aug 2016; status: completed.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on jRCT2080223280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223280.